| (Values in U.S. Thousands) | Apr, 2023 | Jan, 2023 | Oct, 2022 | Jul, 2022 | Apr, 2022 |
| Sales | 1,490 | 1,300 | 860 | 1,090 | 1,160 |
| Sales Growth | +14.62% | +51.16% | -21.10% | -6.03% | +22.11% |
| Net Income | -150 | 0 | -380 | -310 | -80 |
| Net Income Growth | unch | +100.00% | -22.58% | -287.50% | +68.00% |
Polydex Pharmaceuticals Ltd (POLXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Polydex Pharmaceuticals Limited develops and manufactures biotechnology-based products serving markets primarily across North America and globally. The Company primarily focuses on the manufacture and development of Dextran and derivative products. Its product is marketed in human pharmaceutical market and bulk pharmaceutical intermediates for the worldwide pharmaceutical industry. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited. Polydex Pharmaceuticals Limited is based in Toronto, Canada.
Fiscal Year End Date: 01/31